Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duncan H Mak

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Blood|January 12, 2008
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5Bing Z Carter, Duncan H Mak, Wendy D Schober, et al.
Cell Cycle (Georgetown, Tex.)|September 14, 2006
Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistanceBing Z Carter, Duncan H Mak, Yuexi Shi, et al.
Haematologica|February 2, 2023
Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures <i>NPM1/FLT3</i>-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft modelBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Haematologica|August 3, 2019
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine modelBing Z Carter, Po Yee Mak, Hong Mu, et al.
Oncotarget|October 3, 2015
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cellsBing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Blood|November 3, 2010
Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AMLBing Z Carter, Yi Hua Qiu, Nianxiang Zhang, et al.
Oncotarget|March 10, 2016
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling networkBing Z Carter, Po Yee Mak, Ye Chen, et al.
Science Translational Medicine|May 10, 2023
Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficienciesWei Shi, Yin Wang, Yuehui Zhao, et al.
Science Translational Medicine|September 9, 2016
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cellsBing Z Carter, Po Yee Mak, Hong Mu, et al.
Blood|May 31, 2012
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AMLBing Z Carter, Yihua Qiu, Xuelin Huang, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Blood|January 12, 2008
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5Bing Z Carter, Duncan H Mak, Wendy D Schober, et al.
Cell Cycle (Georgetown, Tex.)|September 14, 2006
Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistanceBing Z Carter, Duncan H Mak, Yuexi Shi, et al.
Haematologica|February 2, 2023
Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures <i>NPM1/FLT3</i>-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft modelBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Haematologica|August 3, 2019
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine modelBing Z Carter, Po Yee Mak, Hong Mu, et al.
Oncotarget|October 3, 2015
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cellsBing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Blood|November 3, 2010
Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AMLBing Z Carter, Yi Hua Qiu, Nianxiang Zhang, et al.
Oncotarget|March 10, 2016
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling networkBing Z Carter, Po Yee Mak, Ye Chen, et al.
Science Translational Medicine|May 10, 2023
Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficienciesWei Shi, Yin Wang, Yuehui Zhao, et al.
Science Translational Medicine|September 9, 2016
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cellsBing Z Carter, Po Yee Mak, Hong Mu, et al.
Blood|May 31, 2012
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AMLBing Z Carter, Yihua Qiu, Xuelin Huang, et al.
Pageof 4